Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

Charles A. Peloquin; Patrick P.J. Phillips; Carole D. Mitnick; Kathleen Eisenach; Ramonde F. Patienti; Leonid Lecc; Eduardo Gotuzzo; Neel R. Gandhi; Donna Butler; Andreas H. Diacon; Bruno Martel; Juan Santillan; Kathleen Robergeau Hunt; Dante Vargas; Florian Von Groote-Bidlingmaier; Carlos Seas; Nancy Dianis; Antonio Moreno-Martinez; Pawandeep Kaur; C. Robert Horsburgh

doi:10.1128/AAC.00770-18

Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

Charles A. Peloquin
, Patrick P.J. Phillips
, Carole D. Mitnick
, Kathleen Eisenach
, Ramonde F. Patienti
, Leonid Lecc
, Eduardo Gotuzzo
, Neel R. Gandhi
, Donna Butler
, Andreas H. Diacon
, Bruno Martel
, Juan Santillan
, Kathleen Robergeau Hunt
, Dante Vargas
, Florian Von Groote-Bidlingmaier
, Carlos Seas
, Nancy Dianis
, Antonio Moreno-Martinez
, Pawandeep Kaur
, C. Robert Horsburgh

University of Florida
University of California San Francisco Center for Tuberculosis
MRC Clinical Trials Unit
Harvard Medical School
University of Arkansas for Medical Sciences
TASK Applied Science
Socios en Salud Lima
Rollins School of Public Health
Emory University School of Medicine
Boston University School of Public Health
Westat, Inc.
Universidad Peruana Cayetano Heredia
TB Investigation Unit of Barcelona
Centro de Investigación Biomédica en Red de Epidemiología y Salud Publica
Boston University
Boston University Chobanian & Avedisian School of Medicine

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC_0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (C_max) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)

Original language	English
Article number	e00770
Journal	Antimicrobial Agents and Chemotherapy
Volume	62
Issue number	10
DOIs	https://doi.org/10.1128/AAC.00770-18
State	Published - Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antitubercular agents
Levofloxacin
Pharmacokinetics
Tuberculosis

Access to Document

10.1128/AAC.00770-18

Cite this

Peloquin, C. A., Phillips, P. P. J., Mitnick, C. D., Eisenach, K., Patienti, R. F., Lecc, L., Gotuzzo, E., Gandhi, N. R., Butler, D., Diacon, A. H., Martel, B., Santillan, J., Hunt, K. R., Vargas, D., Von Groote-Bidlingmaier, F., Seas, C., Dianis, N., Moreno-Martinez, A., Kaur, P., & Horsburgh, C. R. (2018). Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis. Antimicrobial Agents and Chemotherapy, 62(10), Article e00770. https://doi.org/10.1128/AAC.00770-18

@article{d721f6924117426d9f4858174262cc1c,

title = "Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis",

abstract = "Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)",

keywords = "Antitubercular agents, Levofloxacin, Pharmacokinetics, Tuberculosis",

author = "Peloquin, \{Charles A.\} and Phillips, \{Patrick P.J.\} and Mitnick, \{Carole D.\} and Kathleen Eisenach and Patienti, \{Ramonde F.\} and Leonid Lecc and Eduardo Gotuzzo and Gandhi, \{Neel R.\} and Donna Butler and Diacon, \{Andreas H.\} and Bruno Martel and Juan Santillan and Hunt, \{Kathleen Robergeau\} and Dante Vargas and \{Von Groote-Bidlingmaier\}, Florian and Carlos Seas and Nancy Dianis and Antonio Moreno-Martinez and Pawandeep Kaur and Horsburgh, \{C. Robert\}",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Microbiology.",

year = "2018",

month = oct,

doi = "10.1128/AAC.00770-18",

language = "Ingl{\'e}s",

volume = "62",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

number = "10",

}

Peloquin, CA, Phillips, PPJ, Mitnick, CD, Eisenach, K, Patienti, RF, Lecc, L, Gotuzzo, E, Gandhi, NR, Butler, D, Diacon, AH, Martel, B, Santillan, J, Hunt, KR, Vargas, D, Von Groote-Bidlingmaier, F, Seas, C, Dianis, N, Moreno-Martinez, A, Kaur, P & Horsburgh, CR 2018, 'Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis', Antimicrobial Agents and Chemotherapy, vol. 62, no. 10, e00770. https://doi.org/10.1128/AAC.00770-18

TY - JOUR

T1 - Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

AU - Peloquin, Charles A.

AU - Phillips, Patrick P.J.

AU - Mitnick, Carole D.

AU - Eisenach, Kathleen

AU - Patienti, Ramonde F.

AU - Lecc, Leonid

AU - Gotuzzo, Eduardo

AU - Gandhi, Neel R.

AU - Butler, Donna

AU - Diacon, Andreas H.

AU - Martel, Bruno

AU - Santillan, Juan

AU - Hunt, Kathleen Robergeau

AU - Vargas, Dante

AU - Von Groote-Bidlingmaier, Florian

AU - Seas, Carlos

AU - Dianis, Nancy

AU - Moreno-Martinez, Antonio

AU - Kaur, Pawandeep

AU - Horsburgh, C. Robert

PY - 2018/10

Y1 - 2018/10

N2 - Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)

AB - Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)

KW - Antitubercular agents

KW - Levofloxacin

KW - Pharmacokinetics

KW - Tuberculosis

UR - https://www.scopus.com/pages/publications/85053940890

U2 - 10.1128/AAC.00770-18

DO - 10.1128/AAC.00770-18

M3 - Artículo

C2 - 30012767

AN - SCOPUS:85053940890

SN - 0066-4804

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 10

M1 - e00770

ER -

Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this